ACS applied bio materials
Cure8 research brief
Why This Matters
Researchers are exploring ways to improve cell therapies for IBD by making therapeutic cells produce anti-inflammatory molecules like IL-10. If scalable and safe, non-viral engineering of MSCs could lead to next-generation cell-and-gene treatments that better reduce gut inflammation.
Who Should Pay Attention
Researchers and clinicians working on cell therapy, gene delivery, and IBD preclinical research; translational scientists interested in non-viral gene-delivery platforms.
Study Snapshot
Story typeResearch paper
Evidence typeResearch paper
Source depthJournal abstract
What To Know
This article reports a preclinical, cell-and-gene engineering study using a non-viral PEG-PEI copolymer to deliver IL-10 transgenes into human mesenchymal stromal cells (MSCs).
Engineered IL-10–overexpressing MSCs were tested in a mouse model of acute colitis where they improved multiple disease measures compared with unmodified or conventionally engineered MSCs.
The platform increased transfection efficiency and anti-inflammatory (IL-10) secretion in primary human MSCs without apparent loss of viability or multipotency in the laboratory assays reported.
In mice, the treatment reduced inflammatory cytokines, promoted epithelial and goblet cell recovery, shifted macrophages toward an M2 phenotype, and normalized pathological angiogenesis while preserving functional vasculature.
This work is a preclinical, proof-of-concept study reported in an abstract/full-text journal article; it demonstrates a gene-delivery method and therapeutic effects in an animal model rather than clinical outcomes in people.
Important steps (safety testing, dose-finding, reproducibility, and human trials) would be required before this approach could become a treatment option for people with IBD.
Keep In Mind
This is a preclinical study using a mouse colitis model and in vitro human MSC experiments. Results in animals or engineered cells do not directly translate to approved human therapies; additional safety and clinical testing are required.
Source Details
Review the original publication for the complete reporting, methods, and context.
Research paper
Evidence type derived from source or registry metadata.
PublicationACS applied bio materials
AuthorsWenting Zhang, Mingmei Yang, Jie Jing +7 more
InstitutionClinical Stem Cell Center, Nanjing Drum Tower Hospital, Clinical Medical College of Traditional Chinese and Western Medicine, Nanjing University of Chinese Medicine, Nanjing, Jiangsu Province210009, China.
Study typeJournal article
Indexed viaPubMed
Source typeResearch paper
PublishedSep 7, 2026, 12:00 AM
Content availableJournal abstract
This Cure8 brief is based on source text from the linked article. Cure8 is informational only and is not a substitute for professional medical advice, diagnosis, or treatment.
Probiotic‐Derived Vesicles Rectally Delivered via Thermo‐Gelling Copolymer Promote Mucosal Healing and Reduce Inflammation in Ulcerative Colitis
This study describes a local rectal therapy that combines mesalamine with probiotic‑derived extracellular vesicles to promote mucosal healing and reduce inflammation in ulcerative colitis models, which could point toward...
Probiotic-Derived Vesicles Rectally Delivered via Thermo-Gelling Copolymer Promote Mucosal Healing and Reduce Inflammation in Ulcerative Colitis.
Localized rectal delivery of probiotic-derived vesicles combined with mesalamine may offer a way to reduce inflammation and help mucosal healing in ulcerative colitis using a stable, off-the-shelf formulation. This could...
Microbiome shift linked to Crohn's disease remission sparks clinical study on new therapy
This reports a potential new way to extend remission after exclusive enteral nutrition by combining diet with fecal microbiome transfer—an approach that targets the gut microbiome rather than adding drugs. If effective,...